Article
Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal…
medRxiv · 2022 · Ou, Y.; Liu, M.; Zhan, K.; Wu, W.; Huang, J.; Sun, H.; Zheng, H.; Yu, X.; Gong, H.; Han, Z.; Chen, A.; Liao, Y.; Lin, Y.; Liu, G.; Liu, Q.; Ma, R.; Mei, Y.; Tang, X.; Weng, Z.; Wu, J.; Ye, Y.; Zhang, T.; Chen, J.; Chen, L.; Ding, Q.; Fan, H.; Hu, J.; Huang, J.; Huang, L.; Li, Q.; Li, S.; Liu, M.; Shi, J.; Tan, X.; Wang, X.; Xiang, R.; Yan, Q.; Zhang, J.; Zheng, W.; Zhong, S.
Key facts
| Title | Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificity |
|---|---|
| First author | Ou, Y.; Liu, M.; Zhan, K.; Wu, W.; Huang, J.; Sun, H.; Zheng, H.; Yu, X.; Gong, H.; Han, Z.; Chen, A.; Liao, Y.; Lin, Y.; Liu, G.; Liu, Q.; Ma, R.; Mei, Y.; Tang, X.; Weng, Z.; Wu, J.; Ye, Y.; Zhang, T.; Chen, J.; Chen, L.; Ding, Q.; Fan, H.; Hu, J.; Huang, J.; Huang, L.; Li, Q.; Li, S.; Liu, M.; Shi, J.; Tan, X.; Wang, X.; Xiang, R.; Yan, Q.; Zhang, J.; Zheng, W.; Zhong, S. |
| Journal | medRxiv |
| Published | Oct 17, 2022 |
| DOI | 10.1101/2022.10.12.511904 |
| Product codes mentioned | JJH |
At a glance
- None FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1